Pain Medications

Fibromyalgia Treatment, Savella, Now Available on Market

June 17, 2009
by: Sylvia Marten

In January 2009, the U.S. Food and Drug Administration (FDA) approved Savella (milnacipran HCl) for the management of fibromyalgia, a muscular pain syndrome known for producing generalized back pain and muscle pain, general feelings of fatigue and specific tender areas.

Savella is now available to consumers by prescription only. It became commercially available in late April. With an estimated six million Americans affected by fibromyalgia each year, Savella is the third FDA-approved medication for this condition behind:

Lyrica (Pregalabin), which was approved in June 2007; and
Cymbalta (Duloxetine HCl), which was approved in June 2008.

While it is unknown how Savella specifically improves the conditions of fibromyalgia, it does inhibit the reuptake of neurotransmitters serotonin and norepinephrine (more so).

Some research has found that norepinephrine, believed to be responsible for feelings of joy, is low in people with fibromyalgia, which is often associated with symptoms of depression. While Savella does not treat depression, it acts like an antidepressant, according to its Medical Guide.

Earlier this year the FDA granted approval of Savella after it statistically showed improvements in pain, global assessment and physical function for more than 2,000 patients with fibromyalgia in two U.S. pivotal phase III clinical trials.

For more on Savella, visit: the official Savella website.

Be sure to check out the Spine-health blog for the latest information and findings on Savella.

Sources: FDA Drug Details for Savella; Forest Laboratories, Inc. Press Release for Savella

More Information on This Topic: